“Personalized medicine is one of the best ways to improve quality and efficiency in healthcare, and reduce costs”, states Brook Byers, a managing partner in the VC firm Kleiner Perkins Caulfield and Byers.

The wealth of information made possible by advancements in genomic science is paving the way for the development of “targeted” diagnostic tests and therapeutics based on an individual’s genetic profile.  This personalized medicine approach holds the potential to revolutionize healthcare by selecting the “right treatment for the right person at the right time”.   What are the commercial opportunities and regulatory challenges posed by the personalized medicine revolution?  And how will this revolution shape the strategies of companies engaged in the development of drugs and diagnostics?

This BioBreakfast program features a panel of preeminent experts who will share some of the exciting commercial breakthroughs as well as the regulatory and legislative developments expected to affect the advancement of personalized medicine in the near-term.  We are pleased to welcome Dr. Janet Woodcock, the FDA’s Director of the Center for Drug Evaluation and Research, as a special guest.  Register now for this timely and informative discussion.

Panelists:

Dr. Stephen Little
Vice President, Personalized Healthcare
QIAGEN

Eric K. Rowinsky, M.D.
Chief Medical Officer
Champions Biotechnology

Christopher Wasden
Managing Director, Strategy and Innovation
Pricewaterhouse Coopers

Janet Woodcock, M.D.
Director, Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Moderator:

Karen Lovitch
Member
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.